The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 12, pp. 1904-1908. DOI 10.1345/aph.1D101
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferrone, M.
Right arrow Articles by Motl, S. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrone, M.
Right arrow Articles by Motl, S. E

DRUG INFORMATION ROUNDS

Trastuzumab for the Treatment of Non–Small-Cell Lung Cancer

Marcus Ferrone, PharmD MS

Clinical Pharmacy Resident, Department of Pharmacy, Columbus Regional Medical Center, Columbus, GA

Susannah E Motl, PharmD

Assistant Professor, University of Tennessee Health Sciences Center, Department of Pharmacy, Drug Information Center, College of Pharmacy, Memphis, TN

Reprints: Marcus Ferrone PharmD MS, Department of Pharmacy, Columbus Regional Medical Center, 710 Center St., Columbus, GA 31902, FAX 706/571-1861, mferrone{at}knology.net

OBJECTIVE: To evaluate trastuzumab for the treatment of advanced non–small-cell lung cancer (NSCLC).

DATA SOURCES: Clinical literature was accessed through MEDLINE (1966–January 2003), EMBASE (1974–January 2003), International Pharmaceutical Abstracts (1970–January 2003), Proceedings of the American Society of Clinical Oncology (1995–January 2003), and Genentech. Key search terms included trastuzumab, lung cancer, Herceptin, and NSCLC.

DATA SYNTHESIS: Research has revealed that NSCLC specimens may express the protein HER-2/neu. The monoclonal antibody against HER-2/neu, trastuzumab, could prove valuable for patients. An evaluation of the studies exploring trastuzumab for management of NSCLC was conducted. Phase II clinical trials reveal variable response rates from no improvement to a partial response rate of 42%. Due to a lack of clinical trials and deficiencies in the literature, the ultimate benefit of this agent remains to be proven.

CONCLUSIONS: Clinical data from ongoing trials indicate potential synergy when trastuzumab is added to standard chemotherapy. The ultimate benefit in NSCLC remains to be proven.

Key Words: Herceptin, non–small-cell lung cancer, trastuzumab

Published Online, October 29, 2003. www.theannals.com, DOI 10.1345/aph.1D101


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. S. Henson, X. Hu, and S. B. Gibson
Herceptin Sensitizes ErbB2-Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression
Clin. Cancer Res., February 1, 2006; 12(3): 845 - 853.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Rosell
Toward Customized Trastuzumab in HER-2/neu-Overexpressing Non-Small-Cell Lung Cancers
J. Clin. Oncol., April 1, 2004; 22(7): 1171 - 1173.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.